D.E. Shaw & Co
RLMD icon

D.E. Shaw & Co’s Relmada Therapeutics RLMD Stock Holding History

D.E. Shaw & Co’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Buy
+109,474
New +$765K ﹤0.01% 3940
2024
Q1 		– Sell
-10,649
Closed -$44.1K – 4669
2023
Q4 		$44.1K Sell
10,649
-8,829
-45% -$26.1K ﹤0.01% 4029
2023
Q3 		$58.4K Sell
19,478
-23,239
-54% -$69K ﹤0.01% 3905
2023
Q2 		$105K Sell
42,717
-1,245
-3% -$3.44K ﹤0.01% 3824
2023
Q1 		$99.4K Buy
43,962
+28,290
+181% +$97.5K ﹤0.01% 3982
2022
Q4 		$54.7K Sell
15,672
-62,534
-80% -$549K ﹤0.01% 4430
2022
Q3 		$2.9M Buy
+78,206
New +$2.17M ﹤0.01% 2669
2022
Q2 		– Sell
-10,487
Closed -$283K – 5705
2022
Q1 		$283K Buy
+10,487
New +$217K ﹤0.01% 4682

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co's RLMD Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 109,474 shares worth $758K. The stake represents ﹤0.01% of the portfolio and ranks #3940 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in RLMD as recently as Q4 2023.

D.E. Shaw & Co first reported a position in RLMD in Q1 2022 and has held it in 8 quarters since. The position peaked at $2.9M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • D.E. Shaw & Co held 109,474 shares of Relmada Therapeutics worth $758K as of Q2 2026.
  • Relmada Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3940 holding.
  • D.E. Shaw & Co first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • D.E. Shaw & Co's Relmada Therapeutics position peaked at $2.9M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.